Skip to main content

Table 1 Differences between ACURASYS and ROSE trials

From: Neuromuscular blocking agents for acute respiratory distress syndrome: how did we get conflicting results?

  ACURASYS (2) ROSE (4)
ARDS definition -AECC -Berlin
Median time to enrollment from ARDS diagnosis -16 (6–29) vs. 18 (6–31) h -8.2 (4.0–16.4) vs. 6.8 (3.3–14.5) h
Sedation targets -Control arm—goal Ramsay score 6 (deep sedation) -Control arm—goal Ramsay score 2–3 (light sedation)
Ventilator strategies -TV 6–8 ml/kg
-Low PEEP (≥ 5 cm H2O)
-TV 6 ml/kg
-High PEEP (≥ 8 cm H2O)
Crude 90-day mortality -31.6% vs. 40.7%, p = 0.08 -42.5% vs. 42.8%; p = 0.93
28-day mortality -23.7% vs. 33.3%, p = 0.05 -36.7% vs. 37.0%, p = NS
Ventilator induced lung injury -Barotrauma: 5.1% vs. 11.7%; p = 0.03
-Pneumothorax: 4.0% vs. 11.7%; p = 0.01
-Barotrauma: 4.0% vs. 6.3%; p = 0.12
-Pneumothorax: 2.8% vs. 5.0%; p = 0.10
Other adverse effects -None -Serious cardiovascular events: NMBA14
vs. Control 4; p = 0.02
  1. AECC American-European Consensus Conference, ARDS acute respiratory distress syndrome, TV tidal volume, PEEP positive end-expiratory pressure, NMBA neuromuscular blocking agent